Antibody Drug Conjugate Market Research, Agency, Business Opportunities with New Players
Antibody
drug conjugate market is expected to grow by 19% by 2023. The antibody drug
conjugate is a crucial biopharmaceutical therapy for cancer treatment. Antibody
drug conjugates are the targeted therapy for the treatment of people suffering
with cancer. It is the important class of highly potent biopharmaceutical
drugs, with intend to target and kill only cancer cells. Antibody drug
conjugates have quality of sensitive discrimination between healthy and
diseased tissue.
Antibody drug conjugates represent an innovative therapeutic
application that combines the unique, high specificity, properties and
anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but
not sufficiently cytotoxic. According to National Instituted of Health (NIH) it
has been found that in 2016, a projected 1,685,210 new cases of cancer will be
detected in the United States and 595,690 individuals will die from the disease
which further increases the growth of the market.
Global Antibody drug conjugate Market- Competitive
Analysis
Seattle Genetics (U.S.), ImmunoGen, Inc.(U.S.), Roche
Holding AG (Switzerland), Genentech (U.S.), Concortis Biotherapeutics (U.S.),
Agensys, Inc. (U.S.), Antikor (U.K), Vaccinex Inc (U.S.) are some of the
leading players at the cutting edge of the competition in the market of
antibody drug conjugate, globally.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1113
Global Antibody drug conjugate Market – Overview
The global antibody drug conjugate market is rising with a
swift phase; mainly owing to increase in patient population suffering with
cancer. This therapy have ability to treat different type of cancer such as
endometrial and breast cancer. According to WHO, in 2015, around 570,000 women
died owing to breast cancer globally, which are approximately 15% of all cancer
deaths among women. Breast cancer is most frequent cancer among the women, and
impacting around 1.5 million women every years. Rising consumer awareness about
treatment with antibody drug conjugate therapy and increasing population globally
leads the antibody drug conjugate market.
Companies are continuously invent new products to capture
the market globally. Thus major players invest more in merger, collaboration,
and acquisition, in order to lead the global market. In this regards, Jazz
Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and
Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products.
Where ImmunoGen will be responsible for the developing of the three ADC
programs prior to any potential opt-in by Jazz. These collaboration help to
introduce new quality drugs for the treatment of the cancer.
In 2017, Vaccinex Inc and Catalent Biologics to collaborate
on antibody-drug conjugate development. In this collaboration company will
combine the ActivMAb antibody with Catalent’s SMARTag conjugation technology,
for generating unique and differentiated molecule to treat cancers. These
collaboration also help in expanding the network around the globe. Which help
companies to reach the patient population and capturing the market.
Additionally, research and development will help company to leads the market.
Increasing in cancer population globally is the factors that leads the market
of antibody drug conjugate.
Global Antibody drug conjugate Market - Regional Analysis
The market of antibody drug conjugate is much higher in the
Americas region, owing to high presence of population diagnosed with cancer and
also have awareness of healthcare. Thus, market players have good opportunity
to maximize their profit with in this region owing to high awareness of
healthcare awareness. According to American Society of Clinical Oncology (ASCO)
the 5-year survival rate for stage I NSCLC is about 47% which falls drastically
to 10% for stage III. The 5-year survival rate for stage IV NSCLC is just
around 1%.
Europe is also consider huge market for antibody drug
conjugate players, owing to present of huge population affected with cancer.
Government are more focusing on research and development to introduce new drugs
for providing the best treatment to their citizen. According to Cancer research
UK, in 2014, new cases of cancer are 356,860, including 579 cases of bone
cancer.
Asia Pacific region is considering the huge market. Whereas
country like India and china of are considering fastest growing region due to
presence of huge population suffering with cancer, additionally they are open
to adopt new technology, and best treatment option from developed countries in
order to improve the quality of life for their public. According to the World
Cancer Research Fund International, in 2015, cancer was responsible for 8.8
million deaths, and is the second leading cause of death across the globe.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment